Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced or Metastatic Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan|DRUG: Capecitabine|DRUG: Paclitaxel|DRUG: Nab-Paclitaxel
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo